Discovery & Early Development Services
KCAS Bio is poised to perform bioanalytical drug discovery including assessment of a compound’s physiochemical properties, metabolite screening, bioavailability, toxicity and pharmacokinetics. KCAS Bio brings the full power of LBA and LC-MS/MS to your Drug Discovery and early stage research projects.
Rapid, rigorous drug discovery services
KCAS Bio organizes teams around early-stage rapid method development and analysis, as well as regulated preclinical and clinical phases, with support offered through NDA submission. We help with study design and perform the TK assessment once the bioanalytical data are available.
Our people
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.
Related services
Resources & insights
Blogs
Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells). There are…
Blogs
KCAS established our clinical sample kit (CSK) team in the early 1990s in response to shortcomings we observed in the collection techniques in trials where we were providing bioanalytical support. As the group has evolved, our aim has never been to be the biggest supplier in the industry but rather…
Blogs
Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the…
Agile, responsive, and easy to work with
We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.